David J. Maron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David J. Maron has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
William E. Boden
Samuel S Stratton Vet Affairs Med Ctr, Albany, NY USA
6 shared publicationsWilliam S. Weintraub
Christiana Care Hlth Syst, Newark, DE USA
6 shared publicationsDaniel S. Berman
4 shared publicationsJohn A. Spertus
4 shared publicationsLeslee J. Shaw
4 shared publicationsPamela M. Hartigan
Vet Affairs Cooperat Studies Program Coordinating, West Haven, CT USA
4 shared publications
Latest Publications
- Open Access
- 1 February 2013
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 6 (1) , 114-121
In Mildly Symptomatic Patients, Should an Invasive Strategy with Catheterization and Revascularization Be Routinely Undertaken?
- 1 February 2013
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 6 (1) , 114-121
Open AccessIn Mildly Symptomatic Patients, Should an Invasive Strategy with Catheterization and Revascularization Be Routinely Undertaken?
- 1 December 2011
- Published by Elsevier in American Heart Journal
- Vol. 162 (6) , 1034-1043.e13
Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists
- 1 December 2011
- Published by Elsevier in American Heart Journal
- Vol. 162 (6) , 1034-1043.e13
Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists
- 1 December 2010
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 13 (1) , 16-25
Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?
Medical therapy is the foundation upon which all treatment for patients with stable coronary artery disease (CAD) is based, regardless of whether revascularization is performed. Although professional societies recommend comprehensive lifestyle and pharmacologic interventions with specific risk factor targets, in practice this does not usually occur. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial tested multiple simultaneous lifestyle and pharmacologic interventions (referred to as “optimal medical therapy” [OMT]) with or without percutaneous coronary intervention (PCI) in patients with stable CAD. Nurse case managers were trained to counsel patients according to protocols designed to achieve predefined lifestyle and risk factor goals. Medications were provided at no cost to patients. Adherence to lifestyle and medication prescription was very high and resulted in significant improvement in risk factor targets. COURAGE found no benefit from the addition of PCI to OMT in the primary outcome of death or myocardial infarction. OMT as delivered in COURAGE has been praised but it has also been criticized as not achievable in “real world” clinical practice. The authors, all COURAGE investigators, believe that the delivery of OMT in COURAGE represents a viable model for secondary prevention that can be translated to real practice, but acknowledge that it is difficult to do so in our fee-for-service health care system. New models of team-based healthcare to achieve evidence-based treatment targets and improved clinical outcomes are needed. Successful translation of COURAGE OMT to everyday practice will require a health care system that rewards quality of care.
- 1 December 2010
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 13 (1) , 16-25
Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?
Medical therapy is the foundation upon which all treatment for patients with stable coronary artery disease (CAD) is based, regardless of whether revascularization is performed. Although professional societies recommend comprehensive lifestyle and pharmacologic interventions with specific risk factor targets, in practice this does not usually occur. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial tested multiple simultaneous lifestyle and pharmacologic interventions (referred to as “optimal medical therapy” [OMT]) with or without percutaneous coronary intervention (PCI) in patients with stable CAD. Nurse case managers were trained to counsel patients according to protocols designed to achieve predefined lifestyle and risk factor goals. Medications were provided at no cost to patients. Adherence to lifestyle and medication prescription was very high and resulted in significant improvement in risk factor targets. COURAGE found no benefit from the addition of PCI to OMT in the primary outcome of death or myocardial infarction. OMT as delivered in COURAGE has been praised but it has also been criticized as not achievable in “real world” clinical practice. The authors, all COURAGE investigators, believe that the delivery of OMT in COURAGE represents a viable model for secondary prevention that can be translated to real practice, but acknowledge that it is difficult to do so in our fee-for-service health care system. New models of team-based healthcare to achieve evidence-based treatment targets and improved clinical outcomes are needed. Successful translation of COURAGE OMT to everyday practice will require a health care system that rewards quality of care.
- 1 October 2009
- Published by Elsevier in The American Journal of Cardiology
- Vol. 104 (8) , 1055-1062
Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial
- 1 October 2009
- Published by Elsevier in The American Journal of Cardiology
- Vol. 104 (8) , 1055-1062
Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial